A PHASE I/II STUDY OF GENASENSE (G3139) IN COMBINATION WITH CISPLATIN AND FLUORO

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。主要目标：研究的升级部分将确定G3139/顺铂的最大耐受剂量（MTD），并将有助于确定该组合的毒性。研究II期部分的主要终点将是缓解率、进展时间和中位生存期。次要目标将是收集该组合的其他毒性数据。在同意活检的患者中，研究人员将致力于确定一些分子标记物和G3139靶点的表达。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Primary objectives: The escalation portion of the study will determine the maximum tolerated dose (MTD) of G3139/ Cisplatin, and will help determine the toxicities of this combination. Primary endpoints of the phase II portion of the study will be response rate, time to progression, and median survival. Secondary objectives will be the collection of additional toxicity data for this combination. In patients who consent to biopsies the investigators will aim to determine the expression of a number of molecular markers and targets of G3139.